These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Erlotinib: as maintenance monotherapy in non-small-cell lung cancer. Muir VJ; Dhillon S BioDrugs; 2011 Jun; 25(3):139-46. PubMed ID: 21513367 [TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR. Mitsuoka S; Kawaguchi T; Kubo A; Isa S; Asai K; Uji M; Watanabe T; Sawa K; Yoshimoto N; Oka T; Nakai T; Suzumura T; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Kudoh S; Hirata K Expert Opin Pharmacother; 2016; 17(2):193-203. PubMed ID: 26781399 [TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342 [TBL] [Abstract][Full Text] [Related]
25. Small molecules with EGFR-TK inhibitor activity. Albanell J; Gascón P Curr Drug Targets; 2005 May; 6(3):259-74. PubMed ID: 15857287 [TBL] [Abstract][Full Text] [Related]
26. Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations. Lyseng-Williamson KA Mol Diagn Ther; 2013 Feb; 17(1):57-62. PubMed ID: 23334845 [TBL] [Abstract][Full Text] [Related]
29. [Erlotinib in non-small cell lung cancer]. Takeda M; Okamoto I Gan To Kagaku Ryoho; 2011 Jun; 38(6):896-900. PubMed ID: 21677478 [TBL] [Abstract][Full Text] [Related]
30. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145 [TBL] [Abstract][Full Text] [Related]
31. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment]. Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245 [TBL] [Abstract][Full Text] [Related]
32. New insights in drug development for the non-small cell lung cancer therapy. Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573 [TBL] [Abstract][Full Text] [Related]
33. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555 [TBL] [Abstract][Full Text] [Related]
34. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Herbst RS; Sandler AB Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S7-S19. PubMed ID: 15638959 [TBL] [Abstract][Full Text] [Related]
35. The role of inhibitors of the epidermal growth factor in management of head and neck cancer. Brockstein B; Lacouture M; Agulnik M J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458 [TBL] [Abstract][Full Text] [Related]
36. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. Sohn HS; Kwon JW; Shin S; Kim HS; Kim H J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867 [TBL] [Abstract][Full Text] [Related]
37. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Smith J Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289 [TBL] [Abstract][Full Text] [Related]
38. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma. Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719 [TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor as a target for chemotherapy. Vallbohmer D; Lenz HJ Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762 [TBL] [Abstract][Full Text] [Related]